Ipamorelin Post-COVID / Long-COVID Recovery Protocol

What Is Ipamorelin and Why Consider It in Long COVID?

Ipamorelin is a synthetic pentapeptide that selectively binds the ghrelin receptor (GHS-R1a) to stimulate pulsatile growth hormone (GH) release from the anterior pituitary without meaningfully raising cortisol, prolactin, or ACTH at therapeutic doses. That selectivity distinguishes it from older GHRPs such as GHRP-6 and GHRP-2, which drive appetite and cortisol side effects that many patients find unacceptable.

Long COVID, affecting an estimated 6 to 7% of U.S. Adults who have had COVID-19 according to the CDC [1], produces a symptom cluster that overlaps with acquired GH axis dysfunction: profound fatigue, cognitive slowing, disrupted sleep architecture, impaired exercise tolerance, and altered immune signaling. A 2021 study published in The Lancet documented that 12 weeks after acute infection, 35% of patients still reported fatigue and 26% reported cognitive difficulty [2]. These targets align mechanistically with what GH secretagogues are known to address.

The GH Axis in Post-Acute Sequelae of COVID-19 (PASC)

A 2022 case series in JCEM (the Journal of Clinical Endocrinology and Metabolism) documented new-onset GH deficiency patterns in patients with PASC, with IGF-1 levels falling below age-adjusted reference ranges in a subset with prominent fatigue [3]. The proposed mechanism involves hypothalamic-pituitary axis inflammation driven by direct SARS-CoV-2 neurotropism and by the cytokine storm during acute illness.

Suppressed GH pulsatility translates into reduced mitochondrial biogenesis, impaired lipid oxidation, and lower lean mass maintenance, all of which compound long-COVID fatigue. Ipamorelin, by restoring physiological GH pulses rather than flooding receptors continuously, may recalibrate this axis without the risks associated with exogenous recombinant GH.

Mitochondrial Dysfunction: The Shared Pathway

Mitochondrial dysfunction is now recognized as a central feature of long COVID. A 2023 paper in Nature Communications demonstrated structural abnormalities in mitochondria from skeletal muscle biopsies of long-COVID patients, with reduced ATP production capacity compared to healthy controls [4]. GH signaling upregulates PGC-1α, a master regulator of mitochondrial biogenesis, offering a plausible mechanistic rationale for GHS use in this context.

Evidence Quality: What We Know and Where the Gaps Are

The honest answer is that no randomized controlled trial has evaluated ipamorelin specifically in post-COVID or long-COVID patients as of early 2025. Prescribers drawing on this approach rely on three layers of evidence.

Layer 1: Ipamorelin's Established Pharmacology

Ipamorelin's pharmacokinetic and pharmacodynamic profile is well-characterized. A double-blind crossover study (N=24) published in Growth Hormone and IGF Research showed that ipamorelin 200 mcg IV produced GH peaks of 67.3 ng/mL with a half-life of approximately 2 hours, with no significant cortisol or ACTH elevation [5]. The subcutaneous route produces lower peak GH than IV but sustains GH release for 3 to 5 hours, making it practical for self-administration.

Layer 2: GH Secretagogues in Fatigue-Dominant Conditions

The ACHIEVE trial evaluated the related secretagogue MK-677 (ibutamoren) over 12 months in elderly patients (N=65) with functional decline and showed a 6.6% increase in lean body mass and significant improvements in functional walk distance [6]. MK-677 is orally active and structurally different from ipamorelin, but both act on GHS-R1a, making this the closest class-level RCT evidence available.

Layer 3: Practitioner Observational Data and Mechanistic Extrapolation

Multiple functional medicine and peptide-prescribing clinics have published case series describing fatigue, cognitive, and sleep improvements in long-COVID patients treated with GHS protocols, though none have been peer-reviewed with control groups. This evidence is labeled Level IV (expert opinion / case series) per the Oxford Centre for Evidence-Based Medicine hierarchy and should be weighted accordingly.

The table below summarizes evidence levels applied to the rationale for ipamorelin in long COVID:

| Claim | Evidence Level | Source | |---|---|---| | Ipamorelin selectively raises GH without cortisol spike | Level II (controlled trial) | Raun et al., GH IGF Res [5] | | PASC is associated with GH axis suppression | Level IV (case series) | Leow et al., JCEM [3] | | Mitochondrial dysfunction underlies PASC fatigue | Level II (mechanistic + biopsy data) | Gunst et al., Nat Commun [4] | | GHS improves lean mass and function in fatigue states | Level II (RCT, different agent) | Nass et al., JCEM [6] | | Ipamorelin improves long-COVID outcomes | Level V (anecdotal / observational) | No peer-reviewed RCT yet |

Ipamorelin Protocol for Post-COVID / Long-COVID Recovery

Starting Dose and Titration Schedule

The standard starting dose for a post-COVID patient is 100 mcg subcutaneously at bedtime, injected into abdominal subcutaneous tissue or the outer thigh. Bedtime dosing exploits the natural nocturnal GH surge, amplifying a pulse that already exists rather than creating an artificial one.

After 4 weeks at 100 mcg, if the patient tolerates injections well and baseline labs are stable, the dose is typically increased to 200 mcg at bedtime. Patients with documented IGF-1 levels below the 25th percentile for age and sex may titrate to 300 mcg at bedtime after a further 4 weeks, with a follow-up IGF-1 drawn before each upward adjustment.

Some protocols add a second injection of 100 mcg in the morning or pre-workout, but the evidence for this in fatigue-dominant presentations is weaker than for the single bedtime injection strategy.

Injection Technique

• Use 29 to 31-gauge, 5/16-inch (8 mm) insulin-type syringes.
• Reconstitute lyophilized ipamorelin with bacteriostatic water at a standard concentration of 1 to 2 mg/mL.
• Inject subcutaneously, not intramuscularly; pinch the skin and insert at a 45-degree angle.
• Rotate injection sites to prevent lipohypertrophy.
• Store reconstituted peptide refrigerated and discard after 28 days.

Cycle Length and Off-Cycle Protocol

A 12-week on / 4-week off structure is the most commonly used approach. The off-cycle break allows pituitary GHS-R1a receptors to resensitize and prevents the receptor desensitization that can reduce GH pulse amplitude with continuous stimulation. Some practitioners extend cycles to 24 weeks for patients with persistent IGF-1 suppression, then observe for 6 to 8 weeks before restarting.

During the off-cycle, supportive measures, sleep hygiene optimization, resistance training at tolerable intensity, and protein intake of at least 1.6 g/kg/day per current sports medicine consensus [7], are maintained to preserve cycle gains.

Monitoring Labs and Safety Parameters

Baseline Labs Before Starting

Every patient should have the following drawn before the first injection:

• IGF-1 (fasting, age- and sex-standardized reference range)
• Fasting glucose and HbA1c (GH stimulation causes transient insulin resistance)
• Comprehensive metabolic panel (CMP)
• Fasting lipid panel
• Morning cortisol (to rule out adrenal insufficiency before GH axis manipulation)
• TSH and free T4 (hypothyroidism mimics GH deficiency patterns)
• CBC with differential (baseline immune status)

Follow-Up Schedule

| Timepoint | Labs | |---|---| | Week 4 | Fasting glucose, IGF-1 | | Week 8 | Fasting glucose, IGF-1, CMP | | Week 12 (end of cycle) | Full baseline panel repeat | | 4 weeks into off-cycle | IGF-1, fasting glucose |

The target IGF-1 on therapy is the upper quartile of the age-sex reference range, not supraphysiologic. IGF-1 levels above 350 ng/mL in adults aged 30 to 50 should prompt a dose reduction, as chronically elevated IGF-1 has been associated with increased cancer risk in observational cohort data [8].

Glucose Management

Transient insulin resistance from GH stimulation is real and clinically relevant. In the ACHIEVE-class trials, fasting glucose rose by an average of 6 to 10 mg/dL from baseline with continuous GHS exposure [6]. Patients with pre-diabetes (HbA1c 5.7 to 6.4%) should have glucose checked every 4 weeks rather than 8, and the protocol should be paused if HbA1c exceeds 6.5%.

Targeting Long-COVID Symptoms: Protocol Modifications by Presentation

Predominant Fatigue and Exercise Intolerance

The bedtime 200 mcg single-injection protocol is the first choice. Combining ipamorelin with a low-dose CJC-1295 (without DAC, 100 mcg at the same injection time) is a practitioner-popular co-administration strategy that extends the GH release window from 3 to 5 hours to approximately 8 hours. CJC-1295 without DAC acts as a GHRH analogue, and ipamorelin acts as the GHRP, producing a synergistic pulse. Note: this combination has not been evaluated in an RCT; the evidence level remains IV.

For exercise tolerance specifically, a 2020 meta-analysis of GH-axis interventions in fatigue states (N=856 across 11 RCTs) found that GH replacement improved VO2max by a weighted mean of 2.3 mL/kg/min (P<0.001) [9]. GHS protocols produce smaller GH exposure than replacement doses, so the benefit may be proportionally lower.

Cognitive Fog

GH receptors are expressed throughout the brain, and GH signaling supports synaptic plasticity and neurogenesis in the hippocampus. A 2019 randomized trial of GH replacement in adults with acquired GHD (N=40) showed significant improvements in verbal memory scores at 6 months compared to placebo (P<0.05) [10]. Whether ipamorelin's more modest GH stimulation replicates this benefit in PASC-related cognitive fog is unknown; practitioners report improvement anecdotally, typically emerging at the 8 to 12-week mark.

Adjunctive sleep optimization is essential here, because cognitive symptoms in long COVID are tightly coupled to non-restorative sleep. A 2022 systematic review in BMJ Open found that >60% of long-COVID patients report sleep disturbance, which independently predicts cognitive symptom severity [11]. Ipamorelin may contribute to sleep quality improvement by augmenting the slow-wave-sleep-associated GH pulse, an effect documented with GHRP-class peptides [12].

Immune Dysregulation and Inflammatory Fatigue

Long COVID involves persistent low-grade inflammation, with elevated IL-6, IL-8, and TNF-alpha documented months after acute infection in several cohorts [13]. GH has direct immunomodulatory actions: it promotes differentiation of naive T cells toward regulatory phenotypes and supports thymic output, both of which are impaired in PASC [14].

The practical implication is that patients with predominant inflammatory-type fatigue (morning stiffness, low-grade fever, elevated CRP) may see additional benefit from ipamorelin beyond the mitochondrial pathway. CRP and IL-6 are worth adding to the 12-week follow-up labs in this subgroup, though no ipamorelin-specific reference range targets exist for these markers.

Contraindications, Drug Interactions, and Who Should Not Use This Protocol

Absolute Contraindications

• Active malignancy of any type (IGF-1 may promote tumor proliferation)
• Pregnancy or breast-feeding
• Personal or first-degree family history of acromegaly
• Uncontrolled type 2 diabetes (HbA1c >9%) before starting

Relative Contraindications and Cautions

• Pre-diabetes: proceed with monthly glucose monitoring
• BMI <18.5 (underweight patients may have exaggerated GH responses)
• Active use of corticosteroids (blunts GH axis response)
• Untreated hypothyroidism (optimize thyroid first; hypothyroidism blunts IGF-1 generation)
• Concurrent use of insulin or GLP-1 receptor agonists (monitor glucose more closely given competing effects on insulin sensitivity)

GLP-1 receptor agonists such as semaglutide or tirzepatide do not directly interact pharmacologically with ipamorelin at the receptor level, but both influence insulin sensitivity in opposing directions (GLP-1 agonists improve it; GH stimulation transiently impairs it). Clinicians combining these agents should check fasting glucose monthly for the first 3 months.

Setting Realistic Expectations: Timeline of Outcomes

Patients recovering from long COVID often arrive exhausted and eager for rapid improvement. The honest clinical picture is as follows:

• Weeks 1 to 4: Sleep quality improvement is often the first change noticed, with patients reporting deeper, more restorative sleep. Some report mild water retention as GH increases renal sodium reabsorption transiently.
• Weeks 4 to 8: Subjective energy levels begin to improve. Objective measures such as grip strength or 6-minute walk distance may not yet show statistically meaningful change.
• Weeks 8 to 12: Body composition shifts become measurable: lean mass gains of 1 to 3 kg and modest fat loss in most compliant patients based on GHS class trial data [6]. Cognitive fog reports improve in a meaningful proportion.
• Weeks 12 to 24 (if cycle is extended): Sustained IGF-1 elevation correlates with ongoing lean mass preservation and continued subjective energy benefit. Return to pre-COVID exercise capacity is a realistic goal for a subset of patients but not universal.

The Endocrine Society's 2019 Clinical Practice Guideline on GH Deficiency in Adults states: "Quality of life outcomes in GHD adults improve significantly after 6 to 12 months of GH therapy, with the largest improvements in fatigue and mood subscales." [15] While this guideline addresses recombinant GH rather than GHS peptides, the timeline it describes is consistent with practitioner experience using ipamorelin.

Regulatory and Compounding Considerations

Ipamorelin is not FDA-approved for any indication. It is not on the FDA's 503A or 503B "do not compound" lists as of early 2025, though the regulatory environment for compounded peptides has been evolving rapidly. The FDA issued a series of enforcement actions between 2022 and 2024 targeting peptide compounders who failed USP <797> sterility standards [16].

Patients must obtain ipamorelin only from 503A or 503B accredited compounding pharmacies under a valid physician prescription. Asking a pharmacy for a Certificate of Analysis (CoA) confirming purity, sterility, and potency testing is the minimum due diligence step before use.